Serotonin function in pathological gambling: Blunted growth hormone response to Sumatriptan

Journal of Psychopharmacology

Volumn 24, Issue 12, 2010, Pages 1802-1809

  Pallanti, Stefano ^a,b,c   Bernardi, Silvia ^a,b   Allen, Andrea ^a   Hollander, Eric ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Psichiatria P   (Italy)

Author keywords

5 HT1B 1D; alcohol; craving; gambling; growth hormone; Sumatriptan

Indexed keywords

GROWTH HORMONE; PLACEBO; PROLACTIN; SEROTONIN; SEROTONIN RECEPTOR; SUMATRIPTAN;

ADULT; ANXIETY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; GROWTH HORMONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; MALE; MOOD; OUTCOME ASSESSMENT; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; REVIEW; SINGLE DRUG DOSE; WITHDRAWAL SYNDROME;

ADULT; ANXIETY; CASE-CONTROL STUDIES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GAMBLING; HUMAN GROWTH HORMONE; HUMANS; MALE; SEROTONIN; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEVERITY OF ILLNESS INDEX; SUMATRIPTAN;

EID: 78650161981     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109106907     Document Type: Review

References (51)

1. Aizenman Y., de Vellis J. (1987) Synergistic action of thyroid hormone, insulin and hydrocortisone on astrocyte differentiation. Brain Res 414: 301-308.
2. Barnes NM, Sharp T. (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083-1152.
3. Benedetti F., Mayberg HS, Wager TD, Stohler CS, Zubieta JK (2005) Neurobiological mechanisms of the placebo effect. J Neurosci 25: 10390-10402.
4. Bezchlibnyk YB, Xu L., Wang JF, Young LT (2007) Decreased expression of insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with bipolar disorder and its regulation by lithium treatment. Brain Res 1147: 213-217.
5. Blier P., Bergeron R. (1995) The safety of concomitant use of sumatriptan and antidepressant treatments. J Clin Psychopharmacol 15: 106-109.
6. Boschert U., Amara DA, Segu L., Hen R. (1994) The mouse 5-hydroxytryptamine1B receptor is localized predominantly on axon terminals. Neuroscience 58: 167-182.
7. Cameron DL, Williams JT (1994) Cocaine inhibits GABA release in the VTA through endogenous 5-HT. J Neurosci 14: 6763-6767.
8. Cameron DL, Williams JT (1995) Opposing roles for dopamine and serotonin at presynaptic receptors in the ventral tegmental area. Clin Exp Pharmacol Physiol 22: 841-845.
9. De Deurwaerdère P., Stinus L., Spampinato U. (1998) Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT3 receptors. J Neurosci 18: 6528-6538.
10. DeCaria C., Begaz T., Hollander E. (1998) Serotonergic and noradrenergic function in pathological gambling. CNS Spectr 3 (6). 38-48.
11. D'Ercole AJ, Ye P., Calikoglu AS, Gutierrez-Ospina G. (1996) The role of the insulin-like growth factors in the central nervous system. Mol Neurobiol 13: 227-255.
12. Eriksson E., Engberg G., Bing O., Nissbrandt H. (1999) Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology 20: 287-296.
13. First M., Spitzer R., Gibbon M., Williams J. (1995) Structured Clinical Interview for the DSM-IV-Patient Version (SCID-I/P, Version 2.0). New York.
14. Florini JR, Prinz PN, Vitiello MV, Hintz RL (1985) Somatomedin-C levels in healthy young and old men: relationship to peak and 24-hour integrated levels of growth hormone. J Gerontol 40: 2-7.
15. Grant JE, Kim SW (2006) Medication management of pathological gambling. Minn Med 89: 44-48.
16. Gross-Isseroff R., Dillon KA, Israeli M., Biegon A. (1990) Regionally selective increases in mu opioid receptor density in the brains of suicide victims. Brain Res 530: 312-316.
17. Guy W. (1976) ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, 218-222.
18. Hamik A., Peroutka SJ (1989) 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 25: 569-575.
19. Hamilton M. (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
20. Herdman JR, Delva NJ, Hockney RE, Campling GM, Cowen PJ (1994) Neuroendocrine effects of sumatriptan. Psychopharmacology (Berl) 113: 561-564.
21. Hollander E., Sood E., Pallanti S., Baldini-Rossi N., Baker B. (2005) Pharmacological treatments of pathological gambling. J Gambl Stud 21: 99-110.
22. Jeggo RD, Wang Y., Jordan D., Ramage AG (2007) Activation of 5-HT1B and 5-HT1D receptors in the rat nucleus tractus solitarius: opposing action on neurones that receive an excitatory vagal C-fibre afferent input. Br J Pharmacol 150: 987-995.
23. Krystal JH, Webb E., Cooney N., Kranzler HR, Charney DS (1994) Specificity of ethanollike effects elicited by serotonergic and nor-adrenergic mechanisms. Arch Gen Psychiatry 51: 898-911.
24. Lesieur HR, Blume SB (1987) The South Oaks Gambling Screen (SOGS). a new instrument for the identification of pathological gamblers. Am J Psychiatry 144: 1184-1188.
25. Leventhal J., Feldman E. (1999) IGFs and the nervous system. In: Rosenfeld R, Roberts C (eds) The IGF System. 425-455.
26. Martin GR (1997) Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia 17 (Suppl 18). 4-14.
27. Middlemiss DN, Bremer ME, Smith SM (1988) A pharmacological analysis of the 5-HT receptor mediating inhibition of 5-HT release in the guinea-pig frontal cortex. Eur J Pharmacol 157: 101-107.
28. Moreno I., Saiz-Ruiz J., Lopez-Ibor J. (1991) Serotonin and gambling dependence. Hum Psychopharmacol 6: 9-12.
29. Moskowitz MA, Cutrer FM (1993) SUMATRIPTAN: a receptor-targeted treatment for migraine. Annu Rev Med 44: 145-154.
30. Moss HB, Hardie TL, Dahl JP, Berrettini W., Xu K. (2007) Diplotypes of the human serotonin 1B receptor promoter predict growth hormone responses to sumatriptan in abstinent alcohol-dependent men. Biol Psychiatry 61: 974-978.
31. Nordin C., Eklundh T. (1999) Altered CSF 5-HIAA Disposition in Pathologic Male Gamblers. CNS Spectr 4: 25-33.
32. Nordin C., Sjodin I. (2006) CSF monoamine patterns in pathological gamblers and healthy controls. J Psychiatr Res 40: 454-459.
33. Pallanti S., Bernardi S., Quercioli L., DeCaria C., Hollander E. (2006) Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo. CNS Spectr 11: 956-964.
34. Pallanti S., DeCaria CM, Grant JE, Urpe M., Hollander E. (2005) Reliability and validity of the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). J Gambl Stud 21: 431-443.
35. Pandey SC, Piano MR, Pandey GN (1996) Alterations in serotonin1B (5HT1B) receptor subtypes in the brain of ethanol-treated rats. Drug Alcohol Depend 41: 219-225.
36. Papageorgiou A., Denef C. (2007) Stimulation of growth hormone release by 5-hydroxytryptamine (5-HT) in cultured rat anterior pituitary cell aggregates: evidence for mediation by 5-HT2B, 5-HT7, 5-HT1B, and ketanserin-sensitive receptors. Endocrinology 148: 4509-4522.
37. Patkar AA, Mannelli P., Hill KP, Peindl K., Pae CU, Lee TH (2006 a) Relationship of prolactin response to meta-chlorophenylpiperazine with severity of drug use in cocaine dependence. Hum Psychopharmacol 21: 367-375.
38. Patkar AA, Mannelli P., Peindl K., Hill KP, Gopalakrishnan R., Berrettini WH (2006 b) Relationship of disinhibition and aggression to blunted prolactin response to meta-chlorophenylpiperazine in cocaine-dependent patients. Psychopharmacology (Berl) 185: 123-132.
39. Pessia M., Jiang ZG, North RA, Johnson SW (1994) Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res 654: 324-330.
40. Potenza MN (2001) The neurobiology of pathological gambling. Semin Clin Neuropsychiatry 6: 217-226.
41. Potenza M., Hollander E. (2002) Pathologic gambling and impulse control disorders. In: Davis K, Charney D, Coyle J, Nemeroff C (eds) Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA: Lippincott Williams and Wilkins, 1425-1443.
42. Roy A., Linnoila M. (1989) CSF studies on alcoholism and related behaviours. Prog Neuropsychopharmacol Biol Psychiatry 13: 505-511.
43. Scott DJ, Stohler CS, Egnatuk CM, Wang H., Koeppe RA, Zubieta JK (2008) Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 65: 220-231.
44. Soubrié P. (1986) Reconciling the role of central serotonin neurones in human and animal behaviour. Behav Brain Sci 9: 319-364.
45. Stein DJ, Van HB, Wessels CJ, Van KJ, Warwick J., Wasserman HJ (1999) Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor. Prog Neuropsychopharmacol Biol Psychiatry 23: 1079-1099.
46. Verheul R., Van den Brink W., Geerlings P. (1999) A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol 34: 197-222.
47. Vescovi PP, Coiro V. (1997) Persistence of defective serotonergic and GABAergic controls of growth hormone secretion in long-term abstinent alcoholics. Alcohol Alcohol 32: 85-90.
48. Vythilingum B., Hugo CJ, Maritz JS, Pienaar W., Stein DJ (2005) Pharmacological challenge with a serotonin 1D agonist in alcohol dependence. BMC Psychiatry 5: 31.
49. Wager T., Feldman Barrett L. (2004) From affect to control: functional specialization of the insula in motivation and regulation. PsycExtra. Available at: http://www.2.bc.edu/∼barretli/pubs/2004/Wager-Edfest-submitted-copy.pdf
50. Yan QS, Zheng SZ, Feng MJ, Yan SE (2005) Involvement of 5-HT1B receptors within the ventral tegmental area in ethanol-induced increases in mesolimbic dopaminergic transmission. Brain Res 1060: 126-137.
51. Zubieta JK, Bueller JA, Jackson LR, et al. (2005) Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci 25: 7754-7762.